CDC lists 5 active multistate outbreaks tied to oysters, raw milk cheese, sprouts, and pet turtles, with recalls in effect for 4 of them.
|Articles|June 30, 2021
Dole Does Voluntary Recall on its Blueberries
Author(s)John Parkinson
The Food and Drug Administration (FDA) said the company is concerned about cyclospora contamination on the company’s Dole Fresh Blueberries brand.
Advertisement
The FDA announced the voluntary recall of the Dole Fresh Blueberries brand due to a concern about cyclospora contamination. No illnesses have been reported this far.
The recall includes various sizes of the blueberry packages with dates ranging from May 28 to June 9. To learn more, see the graphic below with the specific recall information that is on the containers.
Cyclospora is a parasite that can causes Cyclosporiasis, which is an intestinal infection. People can contract Cyclosporiasis after ingesting contaminated food or water. Common symptoms include severe abdominal pain, diarrhea, nausea and vomiting, body aches and fatigue. The infection is treated with antibiotics.
The company announced the recall on June 24, and is limited in scope to the one brand, Dole Fresh Blueberries. The recall includes the exact UPC and lot code combinations identified in the graphic.
Advertisement
Related to this article
The company, Family Farmstead Dairy, issued a raw cheddar recall over potential contamination with Shiga toxin-producing Escherichia coli (STEC) is happening across 7 states.
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
An APP-driven complex outpatient antimicrobial therapy (COpAT) program for patients with bone and joint infections cut mean time to post-discharge follow-up from 20.1 to 9.7 days but did not significantly reduce 30-day readmissions or emergency department visits.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with Staphylococcus aureus Bacteremia (SAB). This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline.
Labcorp data presented at IDWeek 2026 show measles PCR testing nearly quadrupled and positivity rose sharply from April 2025 through March 2026, as clinicians shift toward guideline-recommended molecular testing amid ongoing US outbreaks.
Company announces first AI-designed personalized phage treatment for antibiotic-resistant bacterial infection in human patient.
Advertisement
Advertisement
Trending on Contagion Live
1
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
2
Measles Update: October 30, 2026
3
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
4
Thinking Outside the IV: Implementation of a COpAT Program for Patients With Bone and Joint Infections
5